Nanologica Q3: Nanologica focus the continued development of the inhalation platform NLAB Spiro

Nanologica focus on the continued development of the inhalation platform NLAB Spiro after closing the NIC-001 project (gastroparesis) earlier this autumn. Nanologica has also added prospects in the preparative (Chromatography) business. When prospects are converted into deliveries Nanologica can take advantage of its increased its Silica production capacity. Nanologica's objective remains to convert additional pipeline opportunities over the next 6 to 18 months.

JU

Johan Unnerus

Sign up for free to continue

Already a member?

Sign in

Disclosures and disclaimers

Premium Plan required to unlock

Unlock companies to access

more high quality research.